Hippocrates Research Swiss
The Boutique CRO Advantage: A High-Value Alternative
In today’s clinical landscape, where capital efficiency and hands-on expertise are the primary drivers for Biotech and Medtech companies, Hippocrates Research Swiss stands as a robust alternative to multinational CROs, building on thirty years of experience of the Hippocrates Group. We transform scientific innovation into solid clinical assets through a leaner, more agile, and highly specialised approach.
Our Core Strengths
- Proven Authority: a 30-year uninterrupted track record of success in Phase I First-in-Human (FIH) and First-in-Class trials. We manage product development from Phase I through Phase III, backed by peer-reviewed publications.
- Real Financial Efficiency: an optimised cost structure with significantly lower overhead than “Big CROs”. This allows sponsors to allocate more resources to science and less to administration, ensuring a premium cost-to-benefit ratio.
- Team Seniority & Continuity: we eliminate the “revolving door” turnover typical of large CROs. Your project will not be handed over to junior staff after contract signature. Every trial is managed by experts with 15 to 30 years of real-world experience.
- 2026 Innovation Readiness: agility in implementing Decentralised Clinical Trials (DCTs) via our HomeTrial 360® platform and predictive AI for recruitment. We leverage validated technologies to bring the trial to the patient, enhancing recruitment and retention while reducing site burden.
- Predictive AI Recruitment: we integrate advanced analytics to identify high-potential investigative sites, ensuring timelines are met and minimising unnecessary activation costs.
Your Value Accelerator
Hippocrates Research Swiss is more than a service provider; we are a value accelerator for innovative companies.
- Multidisciplinary Expertise: specialised in managing complex protocols—from Rare Diseases and Oncology to high-tech Medical Devices (Medtech).
- Regulatory Mentoring: we don’t just follow the rules; we help you navigate them. We provide strategic support for accelerated pathways (PRIME, Orphan Drug, Breakthrough Therapy) to shorten time-to-market.
- Total Transparency (Real-Time Data): constant access to study data and KPIs. We eliminate the “black box” approach, giving sponsors full control over progress at all times.
- Strategic Pan-European Hub: a pan-European presence with a strong focus on Switzerland and Italy, providing privileged access to leading European investigators and deep expertise in EMA, FDA, and local regulatory requirements.
- Flexible Collaboration Models: from integrated regulatory consulting to Functional Service Provider (FSP) models, we scale alongside your company’s growth.
Conclusion
In a market where every month of delay costs millions, Hippocrates Research Swiss provides the certainty of a solid, expert, and financially sustainable partner. We bring thirty years of clinical success to your side to turn innovation into therapeutic reality.
Hippocrates Research Swiss: three decades of stability, the agility of the future.
Value Drivers Comparison
| Value Driver | Multinational CROs | Hippocrates Research Swiss |
| Project Team | Sold by Seniors, managed by Juniors. | Constant Seniority: led by experts with 15-30 years of experience. |
| Continuity | High turnover (PMs often change mid-study). | Historical Memory: the team that starts the study finishes it. |
| Cost Structure | High overhead and internal bureaucracy. | Lean Efficiency: competitive rates focused on clinical value. |
| Sponsor Priority | Small Biotechs are often “small fish” in a big pond. | Strategic Partner: every project is a priority; direct access to decision-makers. |
| Flexibility | Rigid processes; slow to handle protocol amendments. | Operational Agility: real-time response and immediate adaptability. |
| Tech Focus | Complex, often heavy, and standardised systems. | Smart Tech: digital trials, remote monitoring, and Predictive AI. |
| FIH Expertise | Standardised approach based on global volumes. | Bespoke Approach: excellence in complex FIH and First-in-Class trials. |
| PROJECT TEAM |
| Sold by Seniors, managed by Juniors. |
| Constant Seniority: led by experts with 15-30 years of experience. |
| CONTINUITY |
| High turnover (PMs often change mid-study). |
| Historical Memory: the team that starts the study finishes it. |
| COST STRUCTURE |
| High overhead and internal bureaucracy. |
| Lean Efficiency: competitive rates focused on clinical value. |
| SPONSOR PRIORITY |
| Small Biotechs are often “small fish” in a big pond. |
| Strategic Partner: every project is a priority; direct access to decision-makers. |
| FLEXIBILITY |
| Rigid processes; slow to handle protocol amendments. |
| Operational Agility: real-time response and immediate adaptability. |
| TECH FOCUS |
| Complex, often heavy, and standardised systems. |
| Smart Tech: digital trials, remote monitoring, and Predictive AI. |
| FIH EXPERTISE |
| Standardised approach based on global volumes. |
| Bespoke Approach: excellence in complex FIH and First-in-Class trials. |